Please login to the form below

Not currently logged in
Email:
Password:

meningitis B

This page shows the latest meningitis B news and features for those working in and with pharma, biotech and healthcare.

GSK doses first patients in phase 3 meningitis vaccine trial

GSK doses first patients in phase 3 meningitis vaccine trial

GSK’s five-in-one candidate targets five meningitis serogroups - A, C, W, Y and B - which account for nearly all cases of invasive meningococcal disease (IMD). ... Although meningococcal disease is uncommon, studies have shown that between 2014-2017,

Latest news

  • Declining childhood vaccination rates ring alarm bells in England Declining childhood vaccination rates ring alarm bells in England

    The figures also showed decreases in coverage of the 5-in-1 vaccine – which protects against diphtheria, tetanus, pertussis (whooping cough), polio and Haemophilus influenza type b (which can cause meningitis) – ... Sheuli Porkess. She pointed to the

  • GSK's Shingrix sails through FDA advisory committee GSK's Shingrix sails through FDA advisory committee

    EvaluatePharma's latest World Preview report predicts that Shingrix will bring in worldwide product sales of $1.13bn in 2022, adding another blockbuster to GSK's vaccine portfolio alongside meningitis B

  • GSK makes case for revaccination with Shingrix GSK makes case for revaccination with Shingrix

    EvaluatePharma's latest World Preview report predicts that Shingrix will bring in worldwide product sales of $1.13bn in 2022, adding another blockbuster to GSK's vaccine portfolio alongside meningitis B

  • Pfizer wins EU approval for MenB vaccine Trumenba Pfizer wins EU approval for MenB vaccine Trumenba

    Pfizer's Trumenba has been approved for the prevention of meningitis B (MenB) in Europe, laying the ground for the first alternative to GlaxoSmithKline's Bexsero, supplies of which have been ... The UK-based Meningitis Research Foundation said it

  • Bexsero halved UK meningitis B cases in first year, says study Bexsero halved UK meningitis B cases in first year, says study

    GlaxoSmithKline's meningitis B vaccine Bexsero has had a dramatic impact on meningitis B cases in the UK, according to a real-world evidence study. ... provides reassurance to parents who have already vaccinated their children or wish to help protect

More from news
Approximately 5 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    franchise. The icing on the cake is Bexsero for the prevention of meningitis B, which has EU approval and orphan drug designation in the US. Also included in the meningitis “goodie ... training. The Liat Influenza A/B Assay, the first test available

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • UK vs US: what makes a successful immunisation programme?

    My challenge started when my daughter Anna was born. The Hepatitis B vaccine is given at birth in the US, and at the time, this was not a part of the ... The Meningitis B vaccine is unique to the UK and since we live in the UK that was easy to get.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...